Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) generates news across respiratory support, blood monitoring, and emerging diagnostics, reflecting its role as a commercial-stage medical device company. Company announcements highlight the FDA-cleared INSPIRA ART100 cardiopulmonary support system, the development of the INSPIRA ART500 oxygenation platform, and progress with the HYLA non-invasive blood sensor, including completion of a clinical study and preparation for regulatory submission.
News coverage also follows Inspira’s strategic move into liquid biopsy diagnostics. The company has outlined a non-binding term sheet and proposed transaction to acquire an advanced liquid biopsy platform focused initially on breast cancer and circulating tumor cell analysis, alongside a concurrent equity investment and a contingent value rights framework for existing shareholders. These updates provide insight into how Inspira aims to extend its expertise in blood-based technologies into oncology diagnostics.
Investors and observers can expect IINN news to include regulatory milestones, such as submissions and anticipated approvals in markets like the United Arab Emirates, as well as updates on binding purchase orders, deployment timelines, and collaborations. Recent items have covered a registered direct offering, a Standby Equity Purchase Agreement, expansion of laboratory infrastructure, and an AI-based training alliance with Bites Learning Ltd. Leadership appointments and shareholder meeting notices also appear in the company’s news flow.
This news page aggregates these developments in one place, helping readers follow Inspira’s clinical, regulatory, commercial, and corporate updates over time.
Inspira (Nasdaq: IINN) announced completion of commercial deployment of its Additively Manufactured Electronics (AME) system at a Tier‑1 U.S. defense customer on April 16, 2026. The delivery includes ongoing supply of proprietary consumables, creating a contractual basis for recurring revenue beyond the initial system sale.
The AME platform targets extreme miniaturization and complex integration needs across quantum computing, integrated photonics, and superconducting systems, and the company cites the deployment as evidence of commercial demand in advanced defense operations.
Inspira Technologies (NASDAQ: IINN) appointed Yoav Rozanovich as Chief Business Officer on April 14, 2026 to accelerate commercial execution after acquiring the Additive Manufacturing of Electronics (AME) business from Nano Dimension. Immediate priorities include integrating active AME revenue streams, driving AME sales conversion, and building quantum connectivity commercial pipelines.
Inspira (Nasdaq: IINN) announced on April 13, 2026 the start of an AME technology implementation with a customer described as one of the world's 10 largest U.S.-based companies. The rollout is already underway at a U.S. R&D facility and targets cryogenic connectivity for quantum computing using Inspira's acquired AME platform.
The company says this engagement validates the AME platform, reflects ongoing commercial activity with a top-tier technology customer, and supports recurring revenue prospects and broader demand from elite technology organizations.
Inspira (Nasdaq: IINN) is entering the quantum computing sector by directing its newly acquired additive manufactured electronics (AME) platform toward a 3D connectivity architecture for dilution cryostats. The company says the AME platform, developed with more than $200 million invested, has demonstrated proof of concept for qubit-related device integration.
Inspira intends to change its corporate name to QTREX Ltd. pending shareholder approval and is exploring collaborations while maintaining separate commercialization efforts for its medical products.
Inspira (Nasdaq: IINN) announced acquisition of Nano Dimension’s AME platform, acquiring intellectual property, high-precision 3D electronic printing systems, software, engineering know-how, equipment, inventory, customer-related assets and fully equipped facilities.
Total consideration is up to $12.5 million: a $2.0 million upfront cash payment and up to $10.5 million deferred payments tied to platform performance over the next 12 months; closing remains subject to customary regulatory approvals. Inspira assumed control effective immediately and will provide a further strategic update shortly.
Inspira Technologies (Nasdaq: IINN) has terminated its February 17, 2026 sales agreement with A.G.P./Alliance Global Partners and its December 12, 2025 Standby Equity Purchase Agreement with YA II PN, Ltd.
The company delivered formal written notices and stated there are no outstanding obligations or further advances under either agreement, citing a disciplined capital structure as it prepares for its next strategic phase.
Inspira (Nasdaq: IINN) reported full-year 2025 results and business updates on March 26, 2026, highlighting clinical validation and early commercial traction for the INSPIRA ART100 system.
Key points: $289k 2025 revenue from initial deployments, $49.5M binding purchase orders secured in mid-2025 expected to convert to 2026 revenue, R&D $7.496M, operating loss $13.22M, cash $3.159M at year-end, and a subsequent $4.75M registered direct offering boosting liquidity.
Inspira (NASDAQ: IINN, IINNW) received a Nasdaq notice dated Feb 19, 2026, that it is not in compliance with Listing Rule 5550(b)(2) requiring a minimum market value of publicly held shares of $35,000,000.
The company has a 180-day cure period through Aug 18, 2026, to regain compliance by closing at or above $35,000,000 for 10 consecutive business days; trading of ordinary shares continues on Nasdaq.
Inspira Technologies (NASDAQ: IINN, IINNW) deployed its FDA-cleared ART100 system at a leading New York academic medical center ranked in the state top 10. The system was integrated into clinical workflow to begin a structured commercial evaluation aimed at defining protocols and wider institutional adoption.
This deployment expands Inspira's presence in Tier-1 U.S. hospitals and supports the company's ongoing U.S. commercial strategy and evaluations at other major healthcare facilities.
Inspira Technologies (NASDAQ: IINN) will showcase its FDA-cleared ART100 at AmSECT 64th International Conference, March 25–29, 2026, in Austin, Texas, via U.S. distributor Glo-Med Networks.
The company is targeting perfusionists and cardiac surgical teams to accelerate U.S. commercial adoption, leveraging its FDA 510(k) clearance (May 2024) and active distribution channel for clinical integration.